ReviewCancers2025
Unraveling the Burden of Pancreatic Cancer in the 21st Century: Trends in Incidence, Mortality, Survival, and Key Contributing Factors.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?International journal of molecular sciences · 2026Pooled it
- Comparative diagnostic performance of endoscopic ultrasound, MRI, and CT for preoperative assessment of pancreatic cancer: a Bayesian network meta-analysis under a graded reference standard.BMC medical imaging · 2026Pooled it
- The Correlation of Computed Tomography (CT)-Based Body Composition and Survival in Pancreatic Cancer Patients: A Systematic Review.Tomography (Ann Arbor, Mich.) · 2026Pooled it
- From radiomics to transformers in pancreatic cancer detection and prognosis.Frontiers in medicine · 2025Pooled it
- Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study.The British journal of surgery · 2026Article
- Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data.Cancers · 2026Article
- Chitosan-PEG Nanoparticles for Co-Delivery of Paclitaxel and KRAS G12D-Directed siRNA to Pancreatic Cancer Cells.International journal of molecular sciences · 2026Article
- Article
- Nootkatone as a multi-target modulator of the PD-L1/PD-1 signaling in pancreatic cancer: network pharmacology, docking, molecular dynamics, and DFT analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Anti-EGFR liposomal drug delivery system loaded with AGYInternational journal of pharmaceutics: X · 2026Article
- Clinical Presentation and Management Outcomes of Pancreatic Cancer in African Countries: A Scoping Review.Journal of gastrointestinal cancer · 2026Article
- Intratumoral Microbiome of Metastatic Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2026Article
- Review
- Global surge in pancreatic cancer cases driven by ageing populations and modifiable risks.Journal of global health · 2026Article
- Pancreatic Cancer Education: A Scoping Review of Evidence Across Patients, Professionals and the Public.Current oncology (Toronto, Ont.) · 2026Review
- Epigenetic mechanisms linking hexavalent chromium exposure to pancreatic cancer risk: a systematic review.Environmental epigenetics · 2026Review
- Efficacy comparison of radical antegrade modular pancreatosplenectomy versus conventional distal pancreatectomy in the treatment of left-sided pancreatic cancer: a meta-analysis and systematic review.Frontiers in oncology · 2026Review
- Targeting TGF-βR1 Signaling Pathway in Pancreatic Cancer: A Potential Approach with Synthetic Flavanols.Anti-cancer agents in medicinal chemistry · 2026Article
- Survival rate in patients with pancreatic cancer in Guilan province, Iran.Caspian journal of internal medicine · 2026Article
- Pan-cancer profiles of mesothelin (MSLN) unveil diagnostic potential and therapeutic targetability of pancreatic adenocarcinoma.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.